The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma.

Marachelian, Araz; Shimada, Hiroyuki; Sano, Hideki; Jackson, Hollie; Stein, James; Sposto, Richard; Matthay, Katherine K; Baker, David; Villablanca, Judith G

Marachelian, Araz; Shimada, Hiroyuki; Sano, Hideki; Jackson, Hollie; Stein, James; Sposto, Richard; Matthay, Katherine K; Baker, David; Villablanca, Judith G.

Afiliação

Marachelian A; Department of Pediatrics, Children's Hospital Los Angeles, USC Keck School of Medicine, Los Angeles, California, USA. amarachelian@chla.usc.edu

Pediatr Blood Cancer ; 58(5): 675-81, 2012 May.

Article em En | MEDLINE | ID: mdl-22493777

Assuntos

Neuroblastoma/patologia; Pré-Escolar; Humanos; Lactente; Estadiamento de Neoplasias; Neuroblastoma/mortalidade; Neuroblastoma/terapia; Estudos Retrospectivos

Buscar no Google

Imprimir

XML

PubMed Links